LUCD — Lucid Diagnostics Inc.

Summary of Lucid Diagnostics Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Test Volume: 3,664 EsoGuard tests performed in Q4 2025, exceeding the target range of 2,500 to 3,000, marking a 29% increase year-over-year.
• Revenue: $1.5 million for Q4 2025, a 24% increase compared to the previous year.
• Cash Position: $34.7 million at year-end, with an average burn rate of $11.1 million per quarter.
• Operating Expenses: Increased to $48.7 million for 2025 from $44.3 million in 2024, primarily due to increased sales and market access staffing.
• Non-GAAP Loss: $44 million for the year, with a loss per share of $0.10 for Q4 and $0.43 for the year, which is an improvement from the previous year.

2. Strategic Updates and Business Highlights

• Medicare and VA Engagement: Significant progress in securing a contract with the U.S. Department of Veterans Affairs for EsoGuard, aligning pricing with Medicare rates. The VA serves approximately 9 million enrolled veterans, many of whom are at higher risk for esophageal diseases.
• Clinical Evidence: Positive data from a large real-world study involving nearly 12,000 patients, confirming the effectiveness and safety of EsoGuard and EsoCheck.
• Reimbursement Strategy: Ongoing discussions with major payers like UnitedHealthcare and positive engagements with laboratory benefit managers (LBMs) to secure coverage for EsoGuard.
• EHR Integration: Plans to enhance electronic health record (EHR) integration to facilitate test ordering and result delivery.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipation of increased test volumes, particularly from the VA and Medicare, once coverage is secured. The company is optimistic about leveraging its established clinical evidence and commercial relationships to drive growth.
• Sales Strategy: Focus on transitioning sales efforts from event-based testing to direct engagement with physicians and health systems, particularly targeting Medicare patients.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Delays: The company is still awaiting a draft Local Coverage Determination (LCD) from Medicare, which is critical for revenue recognition. This delay affects 40-50% of the addressable patient population.
• Cash Burn Management: While the company is reallocating resources to enhance sales efforts, there is caution regarding operational expenditures in the current capital market environment.
• Dependence on Medicare Approval: The uncertainty surrounding Medicare approval continues to be a significant risk, impacting future revenue potential.

5. Notable Q&A Insights

• Volume Growth: The recent increase in test volumes is attributed to improved team productivity and strategic shifts rather than immediate contributions from the VA.
• Medicare Claims: Approximately 16% of test volume is currently Medicare-related, up from 10-12% in previous quarters, with expectations for further growth.
• Credentialing with UnitedHealthcare: The company views its inclusion in UnitedHealthcare's endoscopy guidelines as a form of de facto coverage, which could expedite contracting discussions.
• Sales Rep Productivity: While the company is cautious about expanding its sales force until Medicare coverage is secured, it is optimistic about increasing productivity and volume through strategic reallocations.

Overall, Lucid Diagnostics is positioned for potential growth in 2026, contingent on Medicare coverage and successful engagement with the VA and commercial payers. However, the ongoing delays in reimbursement processes and cautious cash management remain critical challenges.